VivoSeq
Metabolic & Endocrine

Hereditary Hemochromatosis

6

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Hereditary Hemochromatosis is an early-stage landscape with 6 programs across 5 companies. The most active players are Novartis, Bond Biosciences, Protagonist Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

60/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2B

Bond Biosciences

1 program

Phase 2Protagonist Therapeutics logo

Protagonist Therapeutics

1 program

Phase 2L

La Jolla Pharmaceutical Company

1 program

Phase 2CSL Behring logo

CSL Behring

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Terminated1 · 14%
Withdrawn1 · 14%
Unknown status1 · 14%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis
Not yet recruiting·BBond Biosciences·Phase 1/2·NCT07371793·34 enrolled
A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
Completed·LLa Jolla Pharmaceutical Company·Phase 2·NCT03395704·70 enrolled
PTG-300 in Subjects With Hereditary Hemochromatosis
Completed·Protagonist Therapeutics logoProtagonist Therapeutics·Phase 2·NCT04202965·16 enrolled
Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis
Completed·Novartis logoNovartis·Phase 1/2·NCT00395629·49 enrolled
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
Terminated·Novartis logoNovartis·Phase 2·NCT03203850·45 enrolled
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Withdrawn·HHaukeland University Hospital·Phase 2·NCT01892644
Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis
Unknown status·MMaastricht University Medical Center·N/A·NCT01524757·48 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)